Compare AEYE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEYE | VRCA |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 88.0M |
| IPO Year | 2011 | 2018 |
| Metric | AEYE | VRCA |
|---|---|---|
| Price | $6.66 | $3.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $17.33 | $13.83 |
| AVG Volume (30 Days) | ★ 63.8K | 45.3K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,311,000.00 | $35,577,000.00 |
| Revenue This Year | $8.25 | N/A |
| Revenue Next Year | $10.24 | $58.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 14.52 | ★ 370.22 |
| 52 Week Low | $5.31 | $3.28 |
| 52 Week High | $16.39 | $9.82 |
| Indicator | AEYE | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 31.28 |
| Support Level | $6.61 | N/A |
| Resistance Level | $7.32 | $5.94 |
| Average True Range (ATR) | 0.31 | 0.36 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 9.76 | 3.25 |
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.